Schizophrenia is a chronic and severe psychotic disorder that affects around 1% of the population. Currently, there is no clinical test for diagnosing schizophrenia, and therefore the condition is usually recognized and treated on the basis of patient symptoms.

A new study performed by Matej Orešič and colleagues from VTT Technical Research Centre of Finland in collaboration with Jaana Suvisaari from the Finnish National Institute for Health and Welfare reveals metabolic abnormalities that are associated specifically with schizophrenia, as opposed to other psychotic disorders. These findings, which were published in Genome Medicine in March 2011, might be an important step towards the development of a clinical diagnostic test for schizophrenia.

The team used metabolomics, a high-throughput method for detecting small metabolites, to produce profiles of the serum metabolites associated with schizophrenia, other nonaffective psychosis (ONAP) or affective psychosis. Their analysis indicates that schizophrenia is associated with elevated serum levels of specific triglycerides, indicative of hyperinsulinemia, and also upregulation of the serum amino acid proline. Orešič et al. then combined these metabolic profiles to create a diagnostic model with the potential to discriminate schizophrenia from other psychoses.

This exciting study demonstrates how metabolomics can be a powerful tool for dissecting disease-related metabolic pathways and for identifying candidate diagnostic and prognostic markers in psychiatric research.

Note: If no author is given, the source is cited instead.

• Mental Health Research
• Alzheimer's Research
• Diseases and Conditions

• Schizophrenia
• Mental Health
• Disorders and Syndromes

• Dopamine hypothesis of schizophrenia
• Paranoia
• Psychopathology
• Delusion
• Delusions of parasite infestation
• Psychosis